Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Pharmaceutical Research|August 22, 2007
Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the ratMarian Geldof, Jan Freijer, Ludy van Beijsterveldt, et al.Clinical Pharmacokinetics|August 10, 2010
Risk assessment in extrapolation of pharmacokinetics from preclinical data to humansZvi Teitelbaum, Thierry Lave, Jan Freijer, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2011
A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditionsAshley Strougo, Ashraf Yassen, Walter Krauwinkel, et al.Journal of Clinical Pharmacology|March 29, 2014
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young agesAshley Strougo, Ashraf Yassen, Claire Monnereau, et al.International Journal of Methods in Psychiatric Research|February 6, 2014
Profiling the subjective effects of Δ⁹-tetrahydrocannabinol using visual analogue scalesDaniël Kleinloog, Frits Roozen, Willem De Winter, et al.Journal of Pharmacokinetics and Pharmacodynamics|February 8, 2012
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug developmentAshley Strougo, Thomas Eissing, Ashraf Yassen, et al.Clinical Pharmacokinetics|January 30, 2021
Oxycodone Effect on Pupil Constriction in Recreational Opioid Users: A Pharmacokinetic/Pharmacodynamic Meta-Analysis ApproachAnna Dari, Stefan Buller, Michael Gautrois, et al.The Journal of Pharmacology and Experimental Therapeutics|December 29, 2007
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction modelTamara J van Steeg, Jan Freijer, Meindert Danhof, et al.Journal of Pain Research|November 6, 2019
Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric populationEstelle Watson, Akash Khandelwal, Jan Freijer, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 28, 2010
An example of optimal phase II design for exposure response modellingAlan Maloney, Marloes Schaddelee, Jan Freijer, et al.Pageof 2